DOI 10.1016/j.crad.2025.107202
Comparison of the diagnostic yield of cognitive magnetic resonance (MR)-targeted transperineal and MR-targeted transrectal prostate biopsy techniques in a matched patient cohort.
Аннотация
AIM: Prostate cancer carries a major public health burden. Biopsy of the prostate gland is usually required to confirm its diagnosis. Traditional transrectal ultrasound (TRUS)-guided approaches have been superseded by transperineal (TP) approaches, which have superior safety profiles. Although saturation TP biopsies performed by urologists under general anaesthetic are well documented, there is a paucity in the literature on outcomes of cognitive magnetic resonance (MR)-targeted TP biopsies.
MATERIALS AND
METHODS
A single-centre, retrospective review of MR-targeted TP biopsies performed between August 2022 and August 2023 was conducted. Thirty-two patients who received TP biopsy within 5 years of prior MR-targeted TRUS, without evidence of disease progression on interval magnetic resonance imaging , were included. Histopathology results were compared with the detection of clinically significant prostate cancer (defined as International Society of Urological Pathology grade group ≥2) constituting the primary outcome measure.
METHODS
A single-centre, retrospective review of MR-targeted TP biopsies performed between August 2022 and August 2023 was conducted. Thirty-two patients who received TP biopsy within 5 years of prior MR-targeted TRUS, without evidence of disease progression on interval magnetic resonance imaging , were included. Histopathology results were compared with the detection of clinically significant prostate cancer (defined as International Society of Urological Pathology grade group ≥ 2) constituting the primary outcome measure.
RESULTS
The median age at biopsy was 63 years. Median prostate volume, prostate-specific antigen (PSA), and PSA density were 43.5 mL, 6.2 ng/mL and 0.14 ng/mL/mL, respectively. Overall, 34.3 % of patients were diagnosed with clinically significant prostate cancer on TP, having been diagnosed with clinically insignificant prostate cancer, atypical small acinar proliferation (ASAP), or high-grade prostatic intraepithelial neoplasia at prior TRUS. Of all, 28.1 % of patients with prostate adenocarcinoma (grade group 1) on TRUS subsequently had non-cancer diagnoses on TP. No complications were recorded.
CONCLUSION
This study demonstrates that, in addition to a superior safety profile compared to TRUS, cognitive MR-targeted transrectal ultrasound-guided TP biopsy holds promise in enhancing detection of clinically significant prostate cancer.
Предметные рубрики MeSH
Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.